Key Takeaways
- SOLASTA® Bio now holds 14 granted patents for its peptide-based bioinsecticides, including eight in the U.S. and six in Europe.
- The company reports high efficacy across more than 50 greenhouse and field trials, with results consistently at or above 85% compared to commercial standards.
- New trials in rice, leafy greens, and soft fruit crops demonstrate broad applicability across major geographies.
- No phytotoxicity or negative impact on beneficial insects has been observed in any trials to date.
- SOLASTA® Bio continues U.S. expansion and builds on momentum from its oversubscribed $14 million Series A round in 2024.
SOLASTA® Bio Strengthens IP Portfolio With 14 Granted Patents
SOLASTA® Bio has announced significant progress in expanding its intellectual property portfolio, further securing commercial protection for its next-generation peptide-based bioinsecticides. The company now holds 14 granted patents, including eight in the United States and six in Europe, reinforcing its global IP strategy as it moves toward commercial deployment.
According to SOLASTA® Bio, the expanding patent coverage provides essential validation and commercial security for partners and growers adopting its nature-inspired crop protection technologies.
SOLASTA® Bio Reports Strong Field Trial Performance Across Multiple Crops
Building on more than 50 greenhouse and field trials, SOLASTA® Bio has broadened its trials programme to include rice, leafy greens, and high-value soft fruits. Trials in Thailand targeting plant hoppers in rice crops have delivered promising results, while ongoing trials in the U.S., UK, and Italy continue to demonstrate strong efficacy against Spotted Wing Drosophila in strawberries and other berries.
